Vistagen Therapeutics, Inc. · NASDAQ:VTGN
Vistagen Therapeutics — NobleCon14 (January 2018)
27 slides from Vistagen Therapeutics's conference presentation, Jan 30, 2018
Slide 1: Corporate Presentation
4 VistaGens Therapeutics SP © 4 Corporate Presentation i, NobleCon14 4 > January 29, 2018 DEVELOPING NEW GENERATION MEDICINES FOR DEPRESSION AND OTHER CNS DISORDERS
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements concern our product candidates, our development efforts, our collaborations, our intellectual property, our
Slide 3: VistaGen Overview
staGen Overview NASDAQ: VIGN Clinical-stage, CNS-focused, emphasis on depression, pain and Parkinson's disease levodopa-induced dyskinesia (PD LID) G Potentially transformative clinical catalysts in 2018 and 2019 ‘AV-101, oral new generation antidepressant; new non-opioid alternative for neuropathic
Slide 4: Major Depressive Disorder (MDD) Therapeutics
| Major Depressive Disorder (MDD) Therapeutics SUBSTANTIAL MARKET WITH GROWING UNMET NEED 1 in 10 in US. Over Age 12 OVER ‘Takes an Antidepressant? q 300 MILLION PEOPLE WORLDWIDE SUFFER / —— FROM DEPRESSION? Global Denemson Maer S445 $17 Billion+ xpected to Grow: zou | —1 2020 1 GET MARKET U.S. Drug
Slide 5: Current FDA-Approved Drug Treatments for MDD
rw vistagen.com Ke) VistaGens Current FDA-Approved Drug Treatments for MDD ‘Therapeutics PROBLEMS WITH CURRENT ANTIDEPRESSANTS AND ADJUNCT! PROZAC ZolofE W ombars jepressant: + Often do not work — Initial treatment effective in only 1 of 3 patients + Slow to work — May take 4 to 6 weeks or more to a
Slide 6: Current MDD Drug Treatment Paradigm
| Current MDD Drug Treatment Paradigm ‘Therapeutics SE | scconoune | z= SSRI/SNRI ‘SSRI/SNRI ‘SSRI/SNRI 4-6 Weeks or more 4-6 Weeks or more 4-6 Weeks or more | | (ttn
Slide 7: Initial Target in Current MDD Drug Treatment Paradigm
K@), Initial Target in Current MDD Drug Treatment Paradigm veces ‘AV-101’S INITIAL FIT, AS A NEW GENERATION ADJUNCTIVE THERAPY wrrweistagen.com SSRI/SNRI SSRI/SNRI SSRI/SNRI 4-6 Weeks or more 4-6 Weeks or more 4-6 Weeks or more | | we Adjunctive Atypical /ankins(ehbticd Initial Objective - Displace
Slide 8: Ketamine is Driving a Paradigm Shift in the Treatment of MDD
VistaGens ‘Therapeutics | Ke), Ketamine is Driving a Paradigm Shift in the Treatment of MDD |NIH)) National institute of Mental Health “Recent data suggest that ketamine, given intravenously, might be the most important through in antidepressant treatment in decades.” Thomas Insel Former Director -
Slide 9: The Ketamine Story
| . VistaGen» The Ketamine Story ‘Therapeutics A PARADIGM SHIFT TOWARDS NEW GENERATION ANTIDEPRESSANTS 4 FDA-approved Currently, only Popular Club Drug: anesthetic available by injection “Special K” MOA is fundamentally different from all FDA-approved antidepressants and adjunctive atypical antipsyc
Slide 10: NIMH's Breakthrough Ketamine Study in Treatment-resistant MDD
rw vistagen.com NIMH’s Breakthrough Ketamine Study in Treatment-resistant MDD ANTIDEPRESSANT EFFECTS WITHIN 1 DAY OF A SINGLE TREATMENT Responder’ Rates at 1 Day with Ketamine in Treatment-resistant MOD * Proportion of patients with treatment- resistant MDD with at least 50% improvement in depressio
Slide 11: Ketamine offers new hope for MDD patients
Ketamine offers new hope for MDD patients, ——- it is it a long-term solution? ; “Club Drug Ketamine Provides Hope in Fight Against Depression” “Drugs to Lift Depressio
Slide 12: AV-101 (4-Chlorokynurenine)
| AV-101 (4-Chlorokynurenine) VistaGens POTENTIAL KETAMINE-LIKE NEW GENERATION TREATMENT FOR MDD % 9 ¢ 9 ° ORAL Prodrug, rapidly absorbed through the gut, actively transported into the brain, converted into it active metabolite, which binds to NMDA receptors FAST-ACTING, KETAMINE-LIKE ANTIDEPRESSANT
Slide 13: AV-101's Mechanism of Action
wrrweistagen.com Ke) AV-101’s Mechanism of Action vee AV-101'S ACTIVE METABOLITE (7-CI-KYNA) INHIBITS NMDA RECEPTOR ACTIVITY NMDA Receptor Pharmacology ° ae ~ etiorat murenion acre 9 ct aba it Classic channel-blocking antagonist 7-<blorotynureni aid = Ketamine met sa ad Lanicemine Phencycidine
Slide 14: AV-101 vs. Ketamine
| AV-101 vs. Ketamine PRECLINICAL EVIDENCE OF KETAMINE- LIKE ANTIDEPRESSANT EFFECTS WITHOUT KETAMINE-LIKE SAFETY CONCERNS: S il ; : i Sees The Journal of Pharmacology and Experimental Therapeutics i I tf i i i H l it i { | “The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects,
Slide 15: AV-101 vs. Ketamine in Published Preclinical Studies
wrrweistagen.com AV-101 vs. Ketamine in Published Prec! Benefits AV-101 Ketamine Forced-swim Tallsuspension een Learned-helplessness RO rauivatens Novelty suppressed feeding | Negative Behavioral Effects AV-101 Ketamine Abusive potential No ‘Yes Hyper movement No ‘Yes " Movement sensitization No Yes
Slide 16: NIH Support for AV-101
rw vistagen.com Ke) VistaGen» NIH Support for AV-101 ‘Therapeutics VALUABLE LONG-TERM RELATIONSHIP AND SUPPORT FOR AV-101 DEVELOPMENT Direct funding for AV-101 Preclinical and Phase 1 Clinical and financial support for AV-101 Phase 2 $8.8 million in direct non-dilutive cash awards for support of AV-
Slide 17: NIH-Sponsored AV-101 Phase 1 Safety Studies
wrwsistagen.com _— - VistaGen» NIH-Sponsored AV-101 Phase 1 Safety Studies Therapeutics NO KETAMINE-LIKE SAFETY CONCERNS AV-101 Phase 1a Study AV-101 Phase 1b Study * Randomized, double-blind, placebo-controlled * Randomized, double-blind, placebo-controlied * Single oral dose with sequential dose-e
Slide 18: NIMH-Sponsored AV-101 Phase 2 Monotherapy Study
wrrweistagen.com NIMH-Sponsored AV-101 Phase 2 Monotherapy Study MDD ORAL MONOTHERAPY Principal Investigator: Dr. Carlos Zarate, Jr., NIMH * Single site: NIMH * Double-blind, placebo- controlled, crossover design * Single oral dose monotherapy, in treatment-resistant MDD patients, once per day for 1
Slide 19: AV-101 Phase 2 Adjunctive Treatment Study
AV-101 Phase 2 Adjunctive Treatment Study Therapeutics NEW GENERATION ORAL ADJUNCTIVE TREATMENT FOR INADEQUATE SSRI/SNRI MONOTHERAPY | Ke), Principal Investigator: Primary Endpoint Secondary Endpoints: Dr. Maurizio Fava, Harvard University Etticaey i Ys Sou eae ay Additional widely-accepted mea mood
Slide 20: AV-101 for Neuropathic Pain
rw vistagen.com AV-101 for Neuropathic Pain UNMET MEDICAL NEED RATIONALE EVIDENCE FOR AV-101 NEXT STEP tn lish Atleast 5% of US. population NMA receptor pretrial ude, suffers from severe aitagonists such) as AV-101 reduced Phase 2 study of neuropathic pain; most treated etern ine cant improve neurop
Slide 21: AV-101 for Parkinson's disease levodopa-induced dyskinesia
rw vistagen.com AV-101 for Parkinson’s disease levodopa-induced dyskinesia UNMET MEDICAL NEED RATIONALE EVIDENCE FOR AV-101. NEXT STEP Levodopa is the most effective treatment for Weak NMDA antagonists, AV-101 reduced mean Parkinson's disease (PD), such as amantadine, ate dyskinesia scores by 30% po
Slide 22: Short Time Horizon to Potential Clinical Catalysts
rw vistagen.com Short Time Horizon to Potential Clinical Catalysts 2H FDA green light for AV- 101 Phase 2 MDD adjunctive treatment study ¥ Completed 2017 1H Potential FDA Fast Track designation for AV-101 for MOD ¥ Completed 1H Launch AV-101 Phase 2 MDD adjunctive treatment study 2018 2H Completion
Slide 23: High-Value Peer/Pharma M&A Underscores Upside Potential
” b) High-Value Peer/Pharma M&A Underscores Upside Potential Allergan. (Dp naure Rapastinel Acquired by Allergan after Phase 2 * New generation antidepressant candidate * $571 million in cash at closing * Similar MOA to AV-101 (NMDAR/AMPA) * $1.0+ billion in potential milestone + Ketamine-like antid
Slide 24: Preeminent CNS Clinical and Regulatory Advisors
wrrweistagen.com Preeminent CNS Clinical and Regulatory Advisors HARVARD. UNIVERSITY Maurizio Fava, M.D. Professor of Psychiatry, Harvard Medical School; Director, Division of Clinicat Research, Massachusetts General Hospital (MGH) Research Institute; Executive Director, MGH Clinical Trials Network
Slide 25: Experienced Team Leading Execution
VistaGens Experienced Team Fs Therapeutics Leading Execution ‘Shawn K. Singh Chief Executive Officer + 25 years of experience with biopharmaceutical companies, a healthcare venture capital firm and a profitable CRO + Artemis Neuroscience; SciClone Pharmaceuticals; Cato BloVentures: a >. Cato Researc
Slide 26: VistaGen Highlights
ul i VistaGen Highlights NASDAQ: VTGN Clinical-stage, focused on depression, pain and PD LID G Potentially transformative catalysts in 2018 and 2019 AV-101, oral new generation antidepressant; oral non-opioid alternative for neuropathic pain te» Strong support from NIH VistaGens ‘Therapeutics a Phas
Slide 27: Company Contact
VistaGene Therapeutics Company Contact: Mark A. McPartland VistaGen Therapeutics Inc. Phone: +1 (650) 577-3606 Email: IR@VistaGen.com Website: www.vistagen.com DEVELOPING NEW GENERATION MEDICINES FOR DEPRESSION AND OTHER CNS DISORDERS